𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Ventricular dilatation and brain atrophy in patients with Parkinson's disease with incipient dementia

✍ Scribed by Richard Camicioli; Jennifer Sabino; Myrlene Gee; Thomas Bouchard; Nancy Fisher; Chris Hanstock; Derek Emery; W.R. Wayne Martin


Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
236 KB
Volume
26
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Age‐related ventricular enlargement is accelerated in Alzheimer's disease, but its relationship to cognitive decline in Parkinson's disease is less clear, even though dementia is common in Parkinson's disease. Our goals were to determine if greater enlargement of the ventricles and gray or white matter atrophy occurred in Parkinson's disease patients developing cognitive decline. Older nondemented patients with Parkinson's disease (33) and age‐ and sex‐matched controls (39) were recruited and prospectively assessed for the development of significant cognitive decline over 36 months. Magnetic resonance imaging was obtained every 18 months, and ventricular volume and total brain gray and white matter volumes were measured using reliable segmentation of T1‐weighted volumetric scans. Subjects with incidental intracranial abnormalities, an atypical course, and stroke as well as dropouts were excluded from a cohort of 52 patients and 50 controls. Among 33 patients and 39 controls, 10 patients and 3 controls developed significant cognitive impairment or dementia. Ventricular change and Parkinson's disease status were significantly associated with dementia. Ventricular change was significantly correlated with change in Mini‐Mental Status Examination in the Parkinson's disease with dementia group (r = 0.87, P = .001). Gray matter atrophy was greater in Parkinson's disease with dementia, with similar change over time in both Parkinson's disease and Parkinson's disease with dementia. White matter volumes were not significantly different between Parkinson's disease and Parkinson's disease with dementia; however, the decrease over time might be greater in Parkinson's disease with dementia. Ventricular dilatation occurs early in the course of significant cognitive decline in patients with Parkinson's disease, possibly reflecting both cortical gray and white matter loss. © 2011 Movement Disorder Society


📜 SIMILAR VOLUMES


Brain atrophy rates in Parkinson's disea
✍ Emma J. Burton; Ian G. McKeith; David J. Burn; John T. O'Brien 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB

## Abstract Increased rates of brain atrophy are seen in Alzheimer's disease, but whether rates are similarly increased in other dementias such as Parkinson's disease dementia (PDD) has not been well examined. We determined the rates of brain atrophy using serial magnetic resonance imaging (MRI) in

Hyperhomocysteinemia in levodopa-treated
✍ Stefano Zoccolella; Claudia dell'Aquila; Giovanni Abruzzese; Angelo Antonini; Ub 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 78 KB

## Abstract Dementia is a frequent non‐motor feature of Parkinson's disease (PD). Elevated plasma homocysteine (Hcy) levels have been associated with both cognitive impairment and dementia. Increased Hcy levels have been observed in levodopa‐treated patients with PD. The objective of our study was

Pentagon drawing and neuropsychological
✍ Francesca Cormack; Dag Aarsland; Clive Ballard; Martin J. Tovée 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB 👁 2 views

## Abstract ## Objectives Early and accurate diagnosis of Dementia with Lewy Bodies (DLB) to allow the appropriate clinical treatment is a priority, given reports of severe neuroleptic sensitivity and a preferential response to cholinesterase inhibitors in these patients. There have been suggestio

Cognitive profiles of individual patient
✍ Carmen Cristea Janvin; Jan Petter Larsen; David P. Salmon; Douglas Galasko; Kenn 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB

## Abstract We describe the pattern of cognitive profiles within a community‐based sample of patients with Parkinson's disease (PD) and dementia (PDD) using cluster analyses, and compare the results with data from patients with Alzheimer's disease (AD) and dementia with Lewy bodies (DLB). Fifty pat

Cholinergic and other neurotransmitter m
✍ Paul T. Francis; Elaine K. Perry 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 75 KB

It is now 30 years since the beginning of intensive efforts to understand the neurotransmitter biochemistry of dementia as exemplified by Alzheimer's disease and such studies have led to the development of rational treatment strategies, which are continuing to benefit patients. However, as studies b